Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

9.3%

5 terminated/withdrawn out of 54 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

55%

11 of 20 completed trials have results

Key Signals

17 recruiting11 with results

Enrollment Performance

Analytics

N/A
18(37.5%)
Phase 2
17(35.4%)
Phase 1
12(25.0%)
Early Phase 1
1(2.1%)
48Total
N/A(18)
Phase 2(17)
Phase 1(12)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (54)

Showing 20 of 54 trials
NCT05765500Phase 2Recruiting

RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

Role: collaborator

NCT05327465Not ApplicableRecruiting

Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy

Role: collaborator

NCT05113537Phase 1Recruiting

Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

Role: collaborator

NCT04457232Phase 1Active Not Recruiting

Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation

Role: collaborator

NCT05918263Not ApplicableRecruiting

Exercise for Tumor Suppressive Impact in Men With Prostate Cancer at High-Risk of Progression on Active Surveillance: The REMOVE Trial

Role: collaborator

NCT06826924Not ApplicableRecruiting

7-Days Water-Only Fasting or Ketone Supplementation Trial in Prostate Cancer

Role: collaborator

NCT04090528Phase 2Active Not Recruiting

pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer

Role: collaborator

NCT05471414Not ApplicableActive Not Recruiting

Whole-Food Plant-Based Diet to Control Weight and MetaboInflammation in Overweight/Obese Men With Prostate Cancer

Role: collaborator

NCT06305598Phase 1Recruiting

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer

Role: collaborator

NCT04716725Phase 2Terminated

68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer

Role: collaborator

NCT07050433Recruiting

COMPASS Study for Metastatic Castration-resistant Prostate Cancer

Role: collaborator

NCT05766371Phase 2Recruiting

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

Role: collaborator

NCT06171139Not ApplicableRecruiting

Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer

Role: collaborator

NCT05435495Recruiting

Mechanisms of Resistance to PSMA Radioligand Therapy

Role: collaborator

NCT06040125Not ApplicableRecruiting

Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial

Role: collaborator

NCT06616597Phase 2Recruiting

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

Role: collaborator

NCT05320406Phase 2Active Not Recruiting

RElugolix VErsus LeUprolide Cardiac Trial

Role: collaborator

NCT06059118Phase 2Recruiting

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Role: collaborator

NCT03492424Recruiting

Ablative Therapy in the Management of Prostate Cancer

Role: collaborator

NCT06046040Phase 1Recruiting

TmPSMA-02 in mCRPC

Role: collaborator